FDA OKs Tesaro’s ni­ra­parib for ovar­i­an can­cer, hand­ing the biotech a big win on the la­bel

The FDA has wast­ed no time in giv­ing Tesaro $TSRO a broad ap­proval for the use of its PARP drug ni­ra­parib, which will now be mar­ket­ed as Ze­ju­la as a main­te­nance ther­a­py for re­cur­rent ovar­i­an can­cer.

The OK and the la­bel that came with it rep­re­sents a set­back for Myr­i­ad Ge­net­ics $MYGN, which had ar­gued that its com­pan­ion di­ag­nos­tic would be need­ed to iden­ti­fy a spe­cif­ic group of ovar­i­an can­cer pa­tients with a bio­mark­er in­di­cat­ing that they would most like­ly ben­e­fit. But reg­u­la­tors blew past any di­ag­nos­tic qual­i­fi­ca­tion in giv­ing Tesaro the la­bel that it was look­ing for, vin­di­cat­ing CEO Lon­nie Moul­der’s vow that he could get an OK aimed at a large seg­ment of the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER